Diabetes

Basal insulin peglispro beats glargine for glycemic control

(HealthDay)—For patients with type 2 diabetes, basal insulin peglispro (BIL) provides better glycemic control than insulin glargine, with increased triglycerides, aminotransferases, and liver fat content, according to a ...

Diabetes

Exenatide twice daily deemed efficacious across BMI ranges

(HealthDay)—For patients with type 2 diabetes, exenatide twice daily added to insulin glargine is efficacious across body mass index (BMI) ranges, according to a study published online March 29 in Diabetes, Obesity and ...

Diabetes

Two regimens fail to stop declines in β-cell function

(HealthDay)—Neither glargine followed by metformin nor metformin alone halts the progressive deterioration of β-cell function in youth with impaired glucose tolerance (IGT) or recently-diagnosed type 2 diabetes, according ...

Diabetes

Case report describes insulin autoimmune syndrome

(HealthDay)—In a case report published online May 1 in Diabetes Care, resolution of hypoglycemia and cardiovascular dysfunction after rituximab treatment of insulin autoimmune syndrome is described.

Diabetes

No increased cancer risk with glargine versus human insulin

(HealthDay)—There is no evidence that patients with diabetes who initiate insulin glargine have a higher risk of cancer than similar patients initiating human neutral protamine Hagedorn (NPH) insulin, according to a study ...

Diabetes

Gender-based differences in glycemic control in T2DM

(HealthDay)—For patients with type 2 diabetes, there are gender-based differences in glycemic control and hypoglycemia after insulin treatment, according to research published in the June issue of Diabetes, Obesity and ...

page 1 from 3